Logo

American Heart Association

  189
  0


Final ID:

Discussant: ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis

  • Nativi-nicolau, Jose  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Author Disclosures:
    Jose Nativi-Nicolau: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

More abstracts on this topic:
Discussant: VALOR-HCM

Deswal Anita, Ho Jennifer, Ho Carolyn, Day Sharlene

Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study

Judge Daniel, Masri Ahmad, Obici Laura, Poulsen Steen, Sarswat Nitasha, Shah Keyur, Soman Prem, Cao Xiaofan, Wang Kevin, Pecoraro Maria, Tamby Jean-francois, Gillmore Julian, Katz Leonid, Fox Jonathan, Maurer Mathew, Alexander Kevin, Ambardekar Amrut, Cappelli Francesco, Fontana Marianna, Garcia-pavia Pablo, Grogan Martha, Hanna Mazen

More abstracts from these authors:
Red Flags in New Onset HFpEF that Should Raise Suspicion for Cardiac Amyloidosis

Alexander Kevin, Nativi-nicolau Jose, Raymer David

Evolving Baseline Risk in Patients With Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials

Masri Ahmad, Nativi-nicolau Jose, Wright Richard, Betts Marissa, Lavoie Louis, Shree Aiswarya, Hennum Liana, Tamby Jean-francois, Falvey Heather, Dev Sandesh

You have to be authorized to contact abstract author. Please, Login
Not Available